Open AccessPropafenone hepatotoxicity: Report of a new case and review of the literature
Author(s) -
Lara Younan,
Kassem Barada,
Walid Faraj,
Ayman Tawil,
Mark Jabbour,
Maurice Khoury,
Nadim El-Majzoub,
Mohamad A. Eloubeidi
Publication year - 2013
Publication title -
the saudi journal of gastroenterology/saudi journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.608
H-Index - 32
eISSN - 1998-4049
pISSN - 1319-3767
DOI - 10.4103/1319-3767.118137
Subject(s) - medicine , propafenone , bradycardia , bronchospasm , cyp2d6 , liver toxicity , pharmacology , drug , cytochrome p450 , toxicity , anesthesia , metabolism , heart rate , asthma , blood pressure , atrial fibrillation
Propafenone is a class Ic antiarrhythmic drug. It is a beta-adrenergic blocker that causes bradycardia and bronchospasm. It is metabolized primarily in the liver. Its bioavailability and plasma concentration differ among patients under long-term therapy. They are genetically determined by the hepatic cytochrome P-450 2D6. Hepatic toxicity is highly uncommon. To date, only eight patients were reported in the reviewed world literature. In this article, one new case will be reported emphasizing the importance of medication history taking in patients presenting with new-onset liver enzymes abnormalities.